Abstract
BackgroundSeveral multi-attribute utility instruments (MAUIs) are available from which utilities can be derived for use in cost-utility analysis (CUA). This study provides a review of recommendations from national health technology assessment (HTA) agencies regarding the choice of MAUIs.MethodsA list was compiled of HTA agencies that provide or refer to published official pharmacoeconomic (PE) guidelines for pricing, reimbursement or market access. The guidelines were reviewed for recommendations on the indirect calculation of utilities and categorized as: a preference for a specific MAUI; providing no MAUI preference, but providing examples of suitable MAUIs and/or recommending the use of national value sets; and recommending CUA, but not providing examples of MAUIs.ResultsThirty-four PE guidelines were included for review. MAUIs named for use in CUA: EQ-5D (n = 29 guidelines), the SF-6D (n = 11), HUI (n = 10), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). EQ-5D was a preferred MAUI in 15 guidelines. Alongside the EQ-5D, the HUI was a preferred MAUI in one guideline, with DALY disability weights mentioned in another. Fourteen guidelines expressed no preference for a specific MAUI, but provided examples: EQ-5D (n = 14), SF-6D (n = 11), HUI (n = 9), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). Of those that did not specify a particular MAUI, 12 preferred calculating utilities using national preference weights.ConclusionsThe EQ-5D, HUI, and SF-6D were the three MAUIs most frequently mentioned in guidelines. The most commonly cited MAUI (in 85% of PE guidelines) was EQ-5D, either as a preferred MAUI or as an example of a suitable MAUI for use in CUA in HTA.
Highlights
Several methods of economic evaluation are utilized in health technology assessment (HTA), including cost-utility analysis (CUA), a form of cost-effectiveness analysis that assesses the value of interventions, typically according to the incremental cost per quality-adjusted life-year (QALY)
Which multi-attribute utility instruments are recommended for use in cost-utility analysis?
By far the most common was the EQ-5D, which was cited in 85% of PE guidelines either as the preferred multi-attribute utility instruments (MAUIs) or as an example of a suitable MAUI for use in CUA in HTA economic evaluations
Summary
Several methods of economic evaluation are utilized in health technology assessment (HTA), including cost-utility analysis (CUA), a form of cost-effectiveness analysis that assesses the value of interventions, typically according to the incremental cost per quality-adjusted life-year (QALY). Several MAUIs are available for indirect measurement of utilities in CUA, including the EQ-5D (two versions: EQ-5D-3L and EQ-5D-5L) [1], the Short-Form 6-Dimension (SF-6D) [2], the Health Utilities Index (two versions: HUI2 and HUI3) [3], Assessment of Quality of Life (several versions, e.g. AQoL 6D and 8D) [4], 15D [5], VR-6D [6] and the Quality of Well-Being (QWB) instrument [7]. Fourteen guidelines expressed no preference for a specific MAUI, but provided examples: EQ-5D (n = 14), SF-6D (n = 11), HUI (n = 9), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1) Of those that did not specify a particular MAUI, 12 preferred calculating utilities using national preference weights. The most commonly cited MAUI (in 85% of PE guidelines) was EQ-5D, either as a preferred MAUI or as an example of a suitable MAUI for use in CUA in HTA
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
